Assignee
MIRATI THERAPEUTICS INC
US40 patents
Top patents by PatentIndex Score
US10125134B2Nov 13, 2018
KRas G12C inhibitors
MIRATI THERAPEUTICS INC43 citations96
US10689377B2Jun 23, 2020
KRas G12C inhibitors
MIRATI THERAPEUTICS INC16 citations85
US11267812B2Mar 8, 2022
KRAS G12C inhibitors
MIRATI THERAPEUTICS INC11 citations84
US11453683B1Sep 27, 2022
KRas G12D inhibitors
MIRATI THERAPEUTICS INC13 citations83
US9809541B2Nov 7, 2017
LSD1 inhibitors
MIRATI THERAPEUTICS INC11 citations83
US11091495B2Aug 17, 2021
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC4 citations82
US10647715B2May 12, 2020
KRas G12C inhibitors
MIRATI THERAPEUTICS INC10 citations82
US10633381B2Apr 28, 2020
KRas G12C inhibitors
MIRATI THERAPEUTICS INC8 citations82
US11964989B2Apr 23, 2024
KRas G12D inhibitors
MIRATI THERAPEUTICS INC2 citations71
US11932633B2Mar 19, 2024
KRas G12C inhibitors
MIRATI THERAPEUTICS INC2 citations71
US11220509B2Jan 11, 2022
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC2 citations71
US12208099B2Jan 28, 2025
Combination therapies
MIRATI THERAPEUTICS INC3 citations69
US11890285B2Feb 6, 2024
Combination therapies
MIRATI THERAPEUTICS INC4 citations68
US10266542B2Apr 23, 2019
EZH2 inhibitors
MIRATI THERAPEUTICS INC6 citations67
US12421253B2Sep 23, 2025
Tetrahydropyridopyrimidine pan-KRas inhibitors
MIRATI THERAPEUTICS INC1 citations63
US11548888B2Jan 10, 2023
KRas G12C inhibitors
MIRATI THERAPEUTICS INC1 citations62
US12371435B2Jul 29, 2025
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US12304915B2May 20, 2025
SOS1 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11999753B2Jun 4, 2024
Tetrahydropyridopyrimidine pan-KRas inhibitors
MIRATI THERAPEUTICS INC1 citations61
US11702418B2Jul 18, 2023
SOS1 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11492351B2Nov 8, 2022
MTA-cooperative PRMT5 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11485738B2Nov 1, 2022
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
MIRATI THERAPEUTICS INC0 citations61
US11479551B2Oct 25, 2022
MTA-cooperative PRMT5 inhibitors
MIRATI THERAPEUTICS INC1 citations61
US11787819B2Oct 17, 2023
Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
MIRATI THERAPEUTICS INC0 citations60
US12171765B2Dec 24, 2024
Combination therapies using PRMT5 inhibitors for the treatment of cancer
MIRATI THERAPEUTICS INC0 citations59
US12128048B2Oct 29, 2024
Combination therapies using PRMT5 inhibitors for the treatment of cancer
MIRATI THERAPEUTICS INC0 citations59
US12377101B2Aug 5, 2025
Combination therapies
MIRATI THERAPEUTICS INC0 citations58
US12286431B2Apr 29, 2025
Crystalline forms of a KRas G12C inhibitor
MIRATI THERAPEUTICS INC0 citations58
US12281113B2Apr 22, 2025
Crystalline forms of a KRas G12C inhibitor
MIRATI THERAPEUTICS INC0 citations58
US12527795B2Jan 20, 2026
Compositions of adagrasib and mTOR inhibitors and methods of treatment therewith
MIRATI THERAPEUTICS INC0 citations57
US12485122B2Dec 2, 2025
Combination of palbociclib and adagrasib for lung cancer
MIRATI THERAPEUTICS INC0 citations57
US12336995B2Jun 24, 2025
Combination therapies
MIRATI THERAPEUTICS INC0 citations57
US12466838B2Nov 11, 2025
Crystalline form of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
MIRATI THERAPEUTICS INC0 citations52
US12421228B2Sep 23, 2025
Naphthyridine derivatives as PRC2 inhibitors
MIRATI THERAPEUTICS INC0 citations51
US12398154B2Aug 26, 2025
Azaquinazoline pan-KRas inhibitors
MIRATI THERAPEUTICS INC0 citations51
US12252493B2Mar 18, 2025
Imidazo[1,2-c]pyrimidine derivatives as PRC2 inhibitors for treating cancer
MIRATI THERAPEUTICS INC0 citations51
US10233152B2Mar 19, 2019
LSD1 inhibitors
MIRATI THERAPEUTICS INC0 citations51
US12280055B2Apr 22, 2025
Combination therapies
MIRATI THERAPEUTICS INC0 citations49
US12383503B2Aug 12, 2025
Adagrasib solid pharmaceutical compositions
MIRATI THERAPEUTICS INC0 citations43
US10059668B2Aug 28, 2018
LSD1 inhibitors
MIRATI THERAPEUTICS INC0 citations41